Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by LEO Pharma

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023
From LEO Pharma
Via Business Wire
LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting
From LEO Pharma
Via Business Wire
LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team
From LEO Pharma
Via Business Wire
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Launches AD Days Around the World Campaign to Raise Awareness of the Impact of Atopic Dermatitis Across Cultures
From LEO Pharma
Via Business Wire
LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis
From LEO Pharma
Via Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress
From LEO Pharma
Via Business Wire
LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe atopic dermatitis at 31st EADV Congress
From LEO Pharma
Via Business Wire
LEO Pharma Appoints Paul Navarre New Member of Its Board of Directors
From LEO Pharma
Via Business Wire
LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology
From LEO Pharma
Via Business Wire
LEO Pharma Strengthens Its Commercial Organization
From LEO Pharma
Via Business Wire
LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
From LEO Pharma
Via Business Wire
LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)
From LEO Pharma
Via Business Wire
Adtralza® (tralokinumab) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
LEO Pharma presents interim data from Phase 3 tralokinumab long-term extension trial in moderate-to-severe atopic dermatitis at EADV 30th Congress
From LEO Pharma
Via Business Wire
LEO Pharma presents new Adtralza® (tralokinumab) data following long-term continuous treatment at EADV 30th Congress
From LEO Pharma
Via Business Wire
LEO Pharma and X-Chem Enter Into Discovery Research Agreement
From LEO Pharma
Via Business Wire
Jesper Brandgaard New Chairman of the Board of Directors of LEO Pharma
From LEO Pharma
Via Business Wire
LEO Pharma initiates the first Phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
From LEO Pharma
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.